1 learning resource available for this topic
Biologic therapies for asthma are targeted treatments designed for patients with severe, uncontrolled asthma despite optimal standard therapy. These monoclonal antibodies target specific inflammatory pathways involved in asthma pathogenesis, including IgE, IL-4/IL-13, and IL-5 signaling cascades. Selection of appropriate biologic therapy requires careful phenotyping of the patient's asthma endotype and assessment of specific biomarkers.
Severe asthma involves complex inflammatory cascades driven by Type 2 helper T-cell responses, resulting in increased production of cytokines like IL-4, IL-5, and IL-13. These cytokines promote eosinophil recruitment, IgE production, mucus hypersecretion, and airway remodeling through smooth muscle proliferation and subepithelial fibrosis. Different asthma endotypes exhibit distinct inflammatory patterns, with some patients showing predominantly eosinophilic inflammation while others demonstrate neutrophilic or mixed inflammatory profiles.
Biologic selection requires identification of the patient's asthma phenotype through biomarker assessment including total IgE, specific IgE levels, blood eosinophil counts, and fractional exhaled nitric oxide (FeNO). Anti-IgE therapy (omalizumab) is indicated for allergic asthma with elevated IgE, while anti-IL5 agents (mepolizumab, benralizumab) target eosinophilic asthma with elevated blood eosinophils. Anti-IL4/IL13 therapy (dupilumab) is effective for Type 2-high asthma with elevated eosinophils or FeNO, particularly when comorbid atopic dermatitis is present.